Rare Medical News
Spotlight On
Focal segmental glomerulosclerosis (FSGS)
Focal segmental glomerulosclerosis is scattered mesangial sclerosis that begins in some glomeruli and eventually involves all glomeruli
Prevalence
Age of Onset
ICD-10
N/A
Inheritance
Autosomal dominant
Autosomal recessive
Mitochondrial/Multigenic
X-linked dominant
X-linked recessive
Rare View
5 Facts you should know
FACT
1
It is characterized by scar tissue that forms in some of the glomeruli in the kidney
FACT
2
Key signs and symptoms include proteinuria, water retention, and edema
FACT
3
Diagnosis is established by renal biopsy
FACT
4
FSGS occurs more frequently in adults than in children and is most prevalent in adults aged 45 and older
FACT
5
Black Americans are at least four times more likely to get FSGS in comparison with white Americans
Interest over time
Google searches
Common signs & symptoms
Protein in the urine
Elevated levels of creatinine
Swelling
Current treatments
At the time this analysis was conducted, there were no current treatments for this disease.
Top Clinical Trials
| Title | Description | Phases | Status | Interventions | More Information |
|---|---|---|---|---|---|
| Obinutuzumab in Primary FSGS | The purpose of this study is to evaluate the safety and efficacy of Obinutuzumab in inducing complete or partial remission of proteinuria. | Phase 2 | Recruiting | Drug: Obinutuzumab | Click here for more information |
| Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease | The researchers are testing adalimumab, a treatment which blocks tumor necrosis factor (TNF), to see if it changes levels of urine biomarker levels (TIMP1 and MCP1). | Phase 2 | Recruiting | Drug: adalimumab | Click here for more information |
| Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation | This study will evaluate the use of Acthar in patients to undergo renal transplantation and will measure the rate of FSGS recurrence. | Phase 3 | Recruiting | Drug: Acthar | Click here for more information |
| PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant | This is a phase III, multicenter, randomized, open label, clinical trial to test that hypothesis that plasmapheresis plus rituximab prior to kidney transplantation can prevent recurrent FSGS in children and adults. | Phase 3 | Recruiting | Drug: Rituximab|Procedure: Plasmapheresis | Click here for more information |
| A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS) | The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple intravenous infusions in adult subjects with FSGS. | Phase 2 | Recruiting | Drug: PF-06730512 | Click here for more information |
| A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease | This is a phase 2a study evaluating the safety and tolerability of multiple ascending doses of GFB-887 in patients with diabetic nephropathy (DN), focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change disease (TR-MCD). | Phase 2 | Recruiting | Drug: GFB-887|Drug: Placebo | Click here for more information |
| Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and assess changes in proteinuria after once-daily dosing over the 108-week treatment period. | Phase 2 | Recruiting | Drug: Sparsentan | Click here for more information |
| Atrasentan in Patients With Proteinuric Glomerular Diseases | The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function. | Phase 2 | Recruiting | Drug: Atrasentan | Click here for more information |
Top Treatments in Research
| Agent | Class/Mechanism of Action | Development Status | Company | Clinical Studies | More Information |
|---|---|---|---|---|---|
| Obinutuzumab | Humanized anti-CD20 monoclonal antibody | Phase 2 | Mayo Clinic | Click here for more information | Click here for more information |
| adalimumab | Adalimumab is a monoclonal antibody to human tumor necrosis factor (TNF) alpha | Phase 2 | University of Michigan | Click here for more information | Click here for more information |
| Acthar | ACTH is an important component of the hypothalamic-pituitary-adrenal axis and is often produced in response to biological stress (along with its precursor corticotropin-releasing hormone from the hypothalamus). Its principal effects are increased production and release of cortisol by the cortex of the adrenal gland. | Phase 3 | University of Colorado, Denver | Click here for more information | Click here for more information |
| Rituximab/Plasmapheresis | The antibody binds to the cell surface protein CD20 | Phase 3 | University of Minnesota | Click here for more information | Click here for more information |
| PF-06730512 | An Fc fusion protein that targets the ROBO2/SLIT2 pathway | Phase 2 | Pfizer | Click here for more information | Click here for more information |
| GFB-887 | GFB-887 is a precision-based, podocyte-targeting, small molecule inhibitor of TRPC5, designed specifically to treat individuals with kidney diseases associated with an over-activation of the TRPC5-Rac1 pathway | Phase 2 | Goldfinch Bio, Inc. | Click here for more information | Click here for more information |
| Sparsentan | Sparsentan, which possesses two clinically validated mechanisms of action in a single molecule, works by selectively blocking the action of two potent vasoconstrictor and mitogenic agents, angiotensin II (AII) and endothelin 1 (ET1), at their respective receptors. Sparsentan is highly selective (10,000-fold) for the AII receptor sub-type 1 and the ET receptor sub-type A. As such, Sparsentan combines the properties of an angiotensin receptor blocker (ARB) and an endothelin receptor antagonist (ERA) in the same molecule. | Phase 3 | Travere Therapeutics, Inc. | Click here for more information | Click here for more information |
| Atrasentan | Atrasentan is a selective and potent inhibitor of the endothelin A receptor, or ETA, which has the potential to provide benefit in multiple chronic kidney diseases by reducing proteinuria and having direct anti-inflammatory and anti-fibrotic effects to preserve kidney function. | Phase 2 | Chinook Therapeutics U.S., Inc. | Click here for more information | Click here for more information |